Table 3.
Adjusted odds of PICU mortality, based on duration of pre-intubation respiratory support
| Pre-Intubation HFNC Exposure | Pre-Intubation NIPPV Exposure | ||
|---|---|---|---|
| aOR [95% CI]a | aOR [95% CI]b | ||
| No IC Dx | No IC Dx | ||
| HFNC ≤6hr (n=194) | (reference) | NIPPV ≤6hr (n=262) | (reference) |
| HFNC >6hr (n=250) | 1.44 [0.83– 2.53] | NIPPV >6hr (n=273) | 0.91 [0.56– 1.48] |
| IC, not HCT | IC, not HCT | ||
| HFNC ≤6hr (n=134) | (reference) | NIPPV ≤6hr (n=135) | (reference) |
| HFNC >6hr (n=181) | 0.83 [0.49 – 1.43] | NIPPV >6hr (n=182) | 1.19 [0.70 – 2.04] |
| HCT | HCT | ||
| HFNC ≤6hr (n=44) | (reference) | NIPPV ≤6hr (n=36) | (reference) |
| HFNC >6hr (n=70) | 2.41 [1.05 – 5.55] | NIPPV >6hr (n=64) | 2.53 [1.04 – 6.15] |
Mixed effects model, adjusted for patient-level fixed effects (IC diagnosis, age, gender, PIM-2 score) and center-level fixed effects (mean monthly volume of tracheal intubations), restricted to patients who received HFNC prior to tracheal intubation. For each category of IC status, patients intubated without pre-intubation exposure to HFNC serve as the reference group.
Mixed effects model, adjusted for patient-level fixed effects (IC diagnosis, age, gender, PIM-2 score) and center-level fixed effects (mean monthly volume of tracheal intubations), restricted to patients who received NIPPV prior to tracheal intubation. For each category of IC status, patients intubated without pre-intubation exposure to NIPPV serve as the reference group.
IC: Immunocompromised; HCT: hematopoietic cell transplant; aOR: adjusted odds ratio; CI: confidence interval; HFNC: high-flow nasal cannula; NIPPV: noninvasive positive pressure ventilation.